Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bladder Cancer
Researcher reports NMP22 BladderChek Test detects three times more cases of bladder cancer
February 14th, 2006
Giora Katz, MD, a urologist with the Lake City Veterans' Hospital in Lake City, Florida reported that in a recent bladder cancer clinical trial including veterans hospitals, Matritech's (MZT) NMP22 BladderChek Test detected three times more cases of bladder cancer in symptomatic patients than cytology, the traditional laboratory test. These results were from a new analysis of a large clinical trial published in the Journal of the American Medical Association (JAMA) in February, 2005. JAMA also reported that the point-of-care NMP22 BladderChek Test significantly increased the detection of recurrent bladder cancer, finding 99% of the malignancies when used with...
Source: Cancer Weekly (2006-02-14)
|
